Cargando…
Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape
The past decade has witnessed the evolvement of cancer immunotherapy as an increasingly effective therapeutic modality, evidenced by the approval of two immune-based products by the FDA, that is, the cancer vaccine Provenge (sipuleucel-T) for prostate cancer and the antagonist antibody against cytot...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386616/ https://www.ncbi.nlm.nih.gov/pubmed/22778760 http://dx.doi.org/10.1155/2012/124187 |